Glucocorticoid-induced hypertension and cardiac injury: Effects of mineralocorticoid and glucocorticoid receptor antagonism

Nagoya Journal of Medical Science

Volumn 76, Issue 1-2, 2014, Pages 81-92

  Hattori, Takuya ^a   Murase, Tamayo ^a   Iwase, Erika ^b   Takahashi, Keiji ^a   Ohtake, Masafumi ^a   Tsuboi, Koji ^a   Ohtake, Mayuko ^a   Miyachi, Masaaki ^a   Murohara, Toyoaki ^a   Nagata, Kohzo ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Cardiac atrophy; Diastolic dysfunction; Glucocorticoids; Hypertension

Indexed keywords

EID: 84897873528     PISSN: 00277622     EISSN: 21863326     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res. 2003; 92: 81-87.
2. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res. 1996; 19: 1-8.
3. Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982; 2: 646-649.
4. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC , Leufkens HG, Walker BR. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004; 90: 859-865.
5. Ullian ME. The role of corticosteriods in the regulation of vascular tone. Cardiovasc Res. 1999; 41: 55-64.
6. Hadoke PW, Macdonald L, Logie JJ, Small GR, Dover AR, Walker BR. Intra-vascular glucocorticoid metabolism as a modulator of vascular structure and function. Cell Mol Life Sci. 2006; 63: 565-578.
7. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Current opinion in nephrology and hypertension. 2004; 13: 451-458.
8. Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res. 2009; 72 Suppl 1: 36-41.
9. Dardevet D, Sornet C, Taillandier D, Savary I, Attaix D, Grizard J. Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats. Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. J Clin Invest. 1995; 96: 2113-2119.
10. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996; 335: 1897-1905.
11. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011; 78: 41-44.
12. Shah OJ, Anthony JC, Kimball SR, Jefferson LS. Glucocorticoids oppose translational control by leucine in skeletal muscle. Am J Physiol Endocrinol Metab. 2000; 279: E1185-1190.
13. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008; 197: 1-10.
14. Odedra BR, Millward DJ. Effect of corticosterone treatment on muscle protein turnover in adrenalectomized rats and diabetic rats maintained on insulin. Biochem J. 1982; 204: 663-672.
15. Shin YS, Fink H, Khiroya R, Ibebunjo C, Martyn J. Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression. Anesth Analg. 2000; 91: 322-328.
16. Mangos GJ, Turner SW, Fraser TB, Whitworth JA. The role of corticosterone in corticotrophin (AC TH)-induced hypertension in the rat. J Hypertens. 2000; 18: 1849-1855.
17. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 1999; 33: 981-986.
18. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, Seward JB. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy. J Cardiol. 1995; 26: 357-366.
19. Yamada Y, Tsuboi K, Hattori T, Murase T, Ohtake M, Furukawa M, Ueyama J, Nishiyama A, Murohara T, Nagata K. Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension. Hypertens Res. 2011; 34: 809-816.
20. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, Nagasaka T, Iwase M, Yamada Y, Nakashima N, Yokota M. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension. 2002; 40: 168-174.
21. Miyachi M, Yazawa H, Furukawa M, Tsuboi K, Ohtake M, Nishizawa T, Hashimoto K, Yokoi T, Kojima T, Murate T, Yokota M, Murohara T, Koike Y, Nagata K. Exercise training alters left ventricular geometry and attenuates heart failure in dahl salt-sensitive hypertensive rats. Hypertension. 2009; 53: 701-707.
22. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006; 47: 656-664.
23. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension. 2005; 45: 283-287.
24. Murase T, Hattori T, Ohtake M, Nakashima C, Takatsu M, Murohara T, Nagata K. Effects of estrogen on cardiovascular injury in ovariectomized female DahlS.Z-Lepr(fa)/Lepr(fa) rats as a new animal model of metabolic syndrome. Hypertension. 2012; 59: 694-704.
25. Somura F, Izawa H, Iwase M, Takeichi Y, Ishiki R, Nishizawa T, Noda A, Nagata K, Yamada Y, Yokota M. Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation. 2001; 104: 658-663.
26. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T, Masuyama T. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation. 2004; 109: 2143-2149.
27. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardiovascular disease. Hypertension. 2000; 36: 912-916.
28. Clore JN, Estep H, Ross-Clunis H, Watlington CO. Adrenocorticotropin and cortisol-induced changes in urinary sodium and potassium excretion in man: effects of spironolactone and RU 486. J Clin Endocrinol Metab. 1988; 67: 824-831.
29. Li M, Wen C, Fraser T, Whitworth JA. Adrenocorticotrophin-induced hypertension: effects of mineralocorticoid and glucocorticoid receptor antagonism. J Hypertens. 1999; 17: 419-426.
30. Ong SL, Zhang Y, Whitworth JA. Reactive oxygen species and glucocorticoid-induced hypertension. Clin Exp Pharmacol Physiol. 2008; 35: 477-482.
31. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A. 1990; 87: 10043-10047.
32. W allerath T, Witte K, Schafer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Forstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A. 1999; 96: 13357-13362.
33. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda). 2008; 23: 160-170.
34. Gayan-Ramirez G, Vanderhoydonc F, Verhoeven G, Decramer M. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med. 1999; 159: 283-289.
35. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, Salehian B. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab. 2003; 285: E363-371.
36. McCroskery S, Thomas M, Maxwell L, Sharma M, Kambadur R. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol. 2003; 162: 1135-1147.
37. W elle S, Bhatt K, Pinkert CA. Myofibrillar protein synthesis in myostatin-deficient mice. Am J Physiol Endocrinol Metab. 2006; 290: E409-415.
38. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol. 2006; 209: 501-514.
39. Savary I, Debras E, Dardevet D, Sornet C, Capitan P, Prugnaud J, Mirand PP, Grizard J. Effect of glucocorticoid excess on skeletal muscle and heart protein synthesis in adult and old rats. The British journal of nutrition. 1998; 79: 297-304.
40. Nagase M, Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res. 2009; 32: 649-657.
41. F under JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005; 93: 121-125.